TrialPanorama/TrialPanorama-database huggingface dataset:
Study: NCT04684212

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: LAmbre PlusTM Left Atrial Appendage Closure System
Description: The LAmbre Plus device is a self-expanding occluder, composed of a distal Umbrella and a proximal Cover laser welded together, delivered percutaneously via femoral venous access and trans-septal puncture. The distal Umbrella consists of an elastic nitinol frame and outer PET membrane, and has circumferential anchors to secure the occluder to the left atrial appendage (LAA) wall. The proximal Cover is a disc of elastic nitinol mesh, which seals the orifice of the LAA and minimizes thrombus formation, and includes a PET membrane to prevent the passage of blood into the LAA after implantation.

Intervention type: DEVICE
Group type: OTHER
Intervention: LAmbre PlusTM Left Atrial Appendage Closure System
Description: The LAmbre Plus device is a self-expanding occluder, composed of a distal Umbrella and a proximal Cover laser welded together, delivered percutaneously via femoral venous access and trans-septal puncture. The distal Umbrella consists of an elastic nitinol frame and outer PET membrane, and has circumferential anchors to secure the occluder to the left atrial appendage (LAA) wall. The proximal Cover is a disc of elastic nitinol mesh, which seals the orifice of the LAA and minimizes thrombus formation, and includes a PET membrane to prevent the passage of blood into the LAA after implantation.

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Market approved oral anticoagulation (OAC), such as warfarin (Coumadin), dabigatran (Pradaxa), rivaroxaban (Xarelto), apixiban (Eliquis), edoxaban (Savaysa), or betrixaban (Bevyxxa)
Description: Continuation of market approved OAC drug.
Study: NCT05115903

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Tapered doses of TNFi
Description: To be given subcutaneously via a prefilled syringe/autoinjector (etanercept, adalimumab, certolizumab pegol, golimumab) or intravenously via infusion (infliximab) at increasing dose intervals as specified

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Standard dose of TNFi
Description: To be given subcutaneously via a prefilled syringe/autoinjector (etanercept, adalimumab, certolizumab pegol, golimumab) or intravenously via infusion (infliximab)
Study: NCT05191524

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Constrained induced movement
Description: Practice in two sessions per day (supervised) for 3 days per week, for six consecutive weeks. The unaffected limb will be constraint using a knee immobilizer only during practice sessions. We will perform the interventions under the supervision of a trained physiotherapist.

Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: Proprioceptive Neuromuscular facilitation
Description: Group B will receive PNF intervention given for 30 minutes to the lower limb 3 times a week for 6 weeks
Study: NCT05661799

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Intervention Group
Description: The programme is a PA programme consisting of one weekly session for 12 weeks. The one hour of PA is supplemented by two 15-minute periods. At the end of each session, a PA challenge and a positive reinforcement exercise are proposed for the coming week. At the beginning of the next session, the facilitator has a dedicated time to give feedback on these challenges (successes and difficulties encountered). At the end of each session, the facilitator explains the theme of the next challenge and exercise. For the challenge, three options are proposed. Each participant chooses the option he/she prefers. Positive reinforcement exercises are also offered in the same way. They aim to strengthen motivation, hope and the sense of self-efficacy (SEP). In addition to these two 15-minute sessions, participants are offered a one-and-a-half hour group session for information and experience sharing. The aim of this session is to discuss different themes.

Intervention type: BEHAVIORAL
Group type: ACTIVE_COMPARATOR
Intervention: Control Group
Description: The programme is a PA programme consisting of one weekly session for 12 weeks.
Study: NCT06297798

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Telerehabilitation
Description: The telerehabilitation program will be implemented using Whatsapp and Zoom applications for 40 minutes, 5 days a week. Posture and stabilization exercises will be performed, and the exercises will be performed for 10 weeks.~Posture and Stabilization Exercise Program:~1. Stretching of neck flexor, extensor, and lateral flexor muscles (30 seconds each)~2. Pectoral muscle stretching (30 seconds, 3 repetitions)~3. Isometric neck exercises (10 seconds, 10 repetitions)~4. Rhomboid strengthening exercise (bringing shoulder blades closer together against resistance using a TheraBand) (10 seconds, 10 repetitions)~5. Stretching of hamstring, lumbar lordosis and gastrocnemius muscles (sitting and standing) (30 seconds, 3 repetitions)~6. Pelvic posterior tilt exercise (10 seconds, 10 repetitions)~7. Bridge exercise (20 seconds, 10 repetitions)~8. Single-leg bridge exercise (Right-Left) (10 seconds, 10 repetitions)~9. Plank (starting with 60 seconds, increasing by 10 seconds each week)
Study: NCT04550780

Intervention type: DRUG
Intervention: Mepolizumab
Description: The first administration of mepolizumab.
Study: NCT06507761

Intervention type: OTHER
Group type: SHAM_COMPARATOR
Intervention: Sham
Description: An unrefrigerated room temperature Cold Pack will be wrapped in a towel and applied to the patient's posterior neck and back for 15 minutes while the patient is lying face down.

Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: Hot Pack
Description: Hot pack (55-60 degrees) application will be wrapped in a towel and applied to the back side neck and back of the patient for 15 minutes while the patient is lying face down.
Study: NCT06207214

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Self-help book for university students.
Description: The intervention being tested, is a self-help book for university students based on Acceptance and Commitment Therapy. The book was published in 2021 and is called The Unbreakable Student: 6 Rules for Staying Sane at University. The book is by Dr Nic Hooper.~The self-help book will be posted in paper form to all participants. There are 8 chapters in the book and participants will be given eight weeks to read the book at home (with a suggestion of reading one chapter per week).
Study: NCT06507761

Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: Cold Pack
Description: Cold pack application (2-4 degrees) will be wrapped in a towel and applied to the patient's back side neck and back for 15 minutes while the patient is lying prone.
Study: NCT05477225

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: NovoSorb® BTM
Description: a biodegradable polyurethane porous matrix adhered to a transparent sealing membrane. The sealing membrane is designed to physiologically close the wound limiting evaporative moisture loss during integration of the matrix.

Intervention type: DEVICE
Group type: ACTIVE_COMPARATOR
Intervention: Human Cadaveric Allograft
Description: The donated human tissue (Allograft) used in this study are from Maxxeus Medical, Kettering, OH . Tissue grafts are recovered from deceased human donors. All tissue is recovered, processed, stored and distributed for use in accordance with the standards of the American Association of Tissue Banks (AATB). Tissue is manufactured in a clean room environment, following rigorous quality assurance standards. The procedures executed to manufacture this graft including recovery, donor screening, testing, processing, packaging, labeling, storage, and distribution were performed in compliance with all applicable local, state, and federal regulations, including the U.S. Food and Drug Administration (FDA) regulations published at 21 CFR Part 1271, and the current edition of the American Association of Tissue Banks Standards for Tissue Banking.~The current sizes that are available for this study: 103 sq cm., 154 sq cm and 232 sq. cm
Study: NCT04992637

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: ClockWork
Description: ClockWork is a behavioral weight loss intervention comprised of coaching sessions as well as digital monitoring and feedback tools. It addresses 4 key behaviors related to the CTS, weight, and health and their Amount, Regularity \& Timing-the ART of ClockWork. Women will receive 12 tailored coaching sessions to review their digital monitoring of each key behavior, learn intervention content, and set goals, which are delivered in-person, by phone, or web to fit women's needs postpartum. Coaches will use women's baseline responses to tailor sessions around the key behaviors. The investigators will protocolize real-time monitoring to increase engagement and adherence, and to facilitate just-in-time adaptive reminders, recommendations, and coaching sessions.

Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: Usual Care
Description: Usual Care consists of the standard care that postpartum women receive without any additional intervention components.
Study: NCT05141175

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Hypertension medication algorithm
Description: The algorithm is configured to align medication choices based on the hemodynamic findings from the ICG readings. This decision support tool was created so as to organize these medications based on their mechanism of action and is consistent with the evidence-based treatment of hypertension.

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Impedance Cardiography
Description: The ICG system provides a printed report that indicates whether a person's hemodynamic state is predominantly one that is vasoconstricted, hyperdynamic, or mixed
Study: NCT05597241

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: apimostinel
Description: N-methyl-D-aspartate (NMDA) receptor modulator

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: apimostinel
Description: N-methyl-D-aspartate (NMDA) receptor modulator

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: apimostinel
Description: N-methyl-D-aspartate (NMDA) receptor modulator

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: apimostinel
Description: N-methyl-D-aspartate (NMDA) receptor modulator

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: apimostinel
Description: N-methyl-D-aspartate (NMDA) receptor modulator

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: Placebo

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: Placebo

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: Placebo

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: Placebo

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: Placebo
Study: NCT05219305

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Dental Implant Placement
Description: Placement in an edentulous site that was previously bone grafted in the prior study.

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Dental Implant Placement
Description: Placement in an edentulous site that was previously bone grafted in the prior study.

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Dental Implant Placement
Description: Placement in an edentulous site that was previously bone grafted in the prior study.
Study: NCT04935320

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: HTL0016878.HCl Solution 10 mg
Description: Oral solution fasted

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: HTL0016878.Citrate Capsule 10 mg
Description: Oral capsule fed or fasted

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: HTL0016878.Citrate Capsule 10 mg
Description: Oral capsule fed or fasted
Study: NCT06061536

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Lipovirtide 10mg
Description: Lipovirtide 10mg+3TC+TDF（LP-80：once a week；3TC+TDF：once daily）；

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Lipovirtide 40mg
Description: Lipovirtide 40mg+3TC+TDF（LP-80：once a week；3TC+TDF：once daily）；

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Lipovirtide 60mg
Description: Lipovirtide 60mg+3TC+TDF（LP-80：once every 2 weeks；3TC+TDF：once daily）；

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: DTG
Description: DTG +3TC + TDF（once daily）.
Study: NCT05515081

Intervention type: PROCEDURE
Group type: OTHER
Intervention: blood sample collection
Description: blood sample colletion at regular intervals
Study: NCT04713215

Intervention type: OTHER
Intervention: Questionnaire
Description: A short (approximately 20-minute) questionnaire will be administered to patients and carers who meet the inclusion criteria and who have expressed and interested, and consented to completing the questionnaire.

Intervention type: OTHER
Intervention: Questionnaire
Description: A short (approximately 20-minute) questionnaire will be administered to patients and carers who meet the inclusion criteria and who have expressed and interested, and consented to completing the questionnaire.

Intervention type: OTHER
Intervention: Questionnaire
Description: A short (approximately 20-minute) questionnaire will be administered to patients and carers who meet the inclusion criteria and who have expressed and interested, and consented to completing the questionnaire.

Intervention type: OTHER
Intervention: Questionnaire
Description: A short (approximately 20-minute) questionnaire will be administered to patients and carers who meet the inclusion criteria and who have expressed and interested, and consented to completing the questionnaire.

Intervention type: OTHER
Intervention: Questionnaire
Description: A short (approximately 20-minute) questionnaire will be administered to patients and carers who meet the inclusion criteria and who have expressed and interested, and consented to completing the questionnaire.

Intervention type: OTHER
Intervention: Questionnaire
Description: A short (approximately 20-minute) questionnaire will be administered to patients and carers who meet the inclusion criteria and who have expressed and interested, and consented to completing the questionnaire.
Study: NCT05766423

Intervention type: BEHAVIORAL
Group type: ACTIVE_COMPARATOR
Intervention: The PATTERN Intervention
Description: The intervention components include:~1. An adherence assessment that requests patients to self-report via MyChart about their medication use. The assessment provides a link between the health center and the patient ahead of a regularly scheduled clinic visit.~2. Care alert notifications directed to a nurse pool and/or member of the clinical care team when a medication adherence related problem is identified by the adherence assessment. The alert will also include the type of problem the patient is experiencing (cognitive, psychological, medical, regiment, social and/or economic). Once they receive these alerts, the care team can then activate appropriate staff and/or resources to respond.
Study: NCT04702061

Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: Erector spina plane block before general anaesthesia
Description: After skin infiltration with 2 ml of 2% lidocaine, an 18 G tuohy needle will be directed between the erector spina muscle and the transverse process of the T4 vertebra using the in-plane technique. The location of the needle will be confirmed by hydrodissection with saline after touching the transverse process. After the plan open, 5 ml of 2% lidocaine, 10 ml of 0.5% bupivacaine and 10 ml of saline, including hydrodissection, will be given in a total amount of 25 ml. Then a 20-G epidural catheter will be inserted 3-4 cm and fixed.
Study: NCT05972395

Intervention type: OTHER
Intervention: Localized vs Widespread Mechanical Pain Hypersensitivity
Description: Based on pressure pain threshold mapping, participants will be classified as having either localized mechanical pain hyperalgesia (hyperalgesia limited to the lumbosacral region) or widespread mechanical pain hyperalgesia (hyperalgesia extending beyond the lumbosacral region).

Intervention type: OTHER
Intervention: Localized vs Widespread Mechanical Pain Hypersensitivity
Description: Based on pressure pain threshold mapping, participants will be classified as having either localized mechanical pain hyperalgesia (hyperalgesia limited to the lumbosacral region) or widespread mechanical pain hyperalgesia (hyperalgesia extending beyond the lumbosacral region).
Study: NCT04938089

Intervention type: OTHER
Intervention: Maintenance
Description: Regular compliant individual is defined in the study as a subject attending 100% of his/her recall visits with a maximum interval of 6 months. Irregular compliant individual is defined as a subject who missed at least one of the recall visits but continued to appear on an irregular basis with a maximum interval of 18 months, non-smoker individual is defined as a subject who never smoked, and lastly, smoker individual is defined as a subject who is smoking \> 9 cigarettes per day.

Intervention type: OTHER
Intervention: Maintenance
Description: Regular compliant individual is defined in the study as a subject attending 100% of his/her recall visits with a maximum interval of 6 months. Irregular compliant individual is defined as a subject who missed at least one of the recall visits but continued to appear on an irregular basis with a maximum interval of 18 months, non-smoker individual is defined as a subject who never smoked, and lastly, smoker individual is defined as a subject who is smoking \> 9 cigarettes per day.
Study: NCT04702061

Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: Thoracic epidural block before general anaesthesia
Description: After skin infiltration with 2 ml of 2% lidocaine, an 18 G tuohy needle will be entered through the T4-5 interspinous space (median or paramedian approach). After reaching the thoracic epidural area by loss of resistance method, the epidural catheter will be advanced and fixed to remain 3-4 cm in the epidural area. Following the test dose (2 ml of 2% lidocaine), 3 ml of 2% lidocaine, 5 ml of 0.5% bupivacaine and 5 ml of saline will be administered intermittently in a total volume of 15 ml.
Study: NCT03716037

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Physical Activity for Life (PAL)
Description: The eight-week exercise program (The PAL Study) will incorporate balance, strength, endurance, and flexibility training. The duration of each exercise session, which will be offered three times a week, will be one hour. The supervised exercise session will include 30 minutes of moderate-intensity aerobic exercise, 15 minutes of resistance training, and 15 minutes of stretching and balance training
Study: NCT05853068

Intervention type: DEVICE
Intervention: Mechanical ventilation
Description: Need for endotracheal intubation and invasive mechanical ventilation
Study: NCT05120778

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: exercise training
Description: as appear in arm description.

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: conventional medical treatment
Description: participants will maintain habitual medical treatment prescribed by primary care and specialized physicians from the public health service.

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: conventional medical treatment
Description: participants will maintain habitual medical treatment prescribed by primary care and specialized physicians from the public health service.
Study: NCT03546660

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: SECM capsule
Description: Subjects will swallow a SECM capsule and the SECM imaging will be performed
Study: NCT05541120

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Remote Patient Monitoring
Description: Remote patient monitoring as the intervention is defined as a tablet and Bluetooth-enabled glucometer technology that collects point-of-care (POC) blood glucose data from a patient outside of a traditional clinical setting, and securely transmits this data to Epic for review and potential intervention.
Study: NCT05535699

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: exercises
Description: scapular exercise

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: exercises
Description: scapular exercise
Study: NCT04797312

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Opioid Free Anaesthesia protocol
Description: The OFA protocol begins with a systematic preoperative premedication with clonidine, continues with an adapted intraoperative management without opioid administration, but associating several molecules (clonidine, magnesium, lidocaine, ketamine) and ends with a continued administration of xylocaine up to 1 hour postoperatively in PACU. The use of an opioid in preoperative or intraoperative phases is considered as a deviation from the protocol.~To these different molecules, the use of hypnotic molecules left to the choice of the practitioner and a curare will be systematically associated.

Intervention type: DRUG
Group type: SHAM_COMPARATOR
Intervention: standard practice protocol based on the use of opioids (sufentanil or remifentanil)
Description: Standard anesthetic practices can be summed up as the combination of a hypnotic, a morphinic (sufentanil or remifentanil) and a curare. The use of ketamine is allowed.
Study: NCT06328660

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Lens 1
Description: Frequent replacement silicone hydrogel contact lens for 14 ± 3 days on a daily disposable wearing modality

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Lens 2
Description: Daily disposable silicone hydrogel contact lens for 14 ± 3 days on a daily disposable wearing modality
Study: NCT04285710

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Phototherapy
Description: The key intervention aspect of this study is the application of 15 J/cm2 of 410 nm pulsed light directly onto the infected diabetic wounds of subjects every week over the course of 3 months, allowing for the cumulative exposure of around 180 J/cm2 for the entire study. This 15 J/cm2 weekly dosage of blue light will split up into two sessions every week, with each session applying 7.5 J/cm2 of light treatment. Phototherapy will be applied twice per week, with one phototherapy session occurring directly following the debridement surgery during the first visit of the week and the other session occurring after the study clinician removes the subjects wound dressings at the second visit.
Study: NCT06455644

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: CT group
Description: After completing the AF ablation, select the appropriate LAA occluder based on preoperative CT measurements for implantation.

Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: DSA group
Description: After completing the AF ablation, select the appropriate LAA occluder based on intraoperative DSA measurements for implantation.
Study: NCT04285710

Intervention type: PROCEDURE
Group type: OTHER
Intervention: Debridement Surgery and Wound Dressing
Description: All patients enrolled in the study will undergo standard care and treatment for infected diabetic wounds, which includes the weekly surgical removal of infected necrotic tissue from the diabetic wounds. In addition to debridement, both groups will utilize an antimicrobial wound dressing to cover and treat the infected diabetic wound. The subject's wounds will be dressed with Aquacel Ag Advantage Wound Dressings to protect and treat their diabetic wounds. These dressings will be changed twice a week by clinicians.